EHP-102 |
|
| Other names | EHP102; VCE-003.2; VCE003.2 |
|---|
Routes of administration | Oral[1] |
|---|
| Drug class | Cannabinoid CB2 receptor agonist; PPARγ agonist |
|---|
|
3-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(ethylamino)-4-hydroxy-6-pentylcyclohexa-3,5-diene-1,2-dione
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| DrugBank | |
|---|
| UNII | |
|---|
|
| Formula | C23H35NO3 |
|---|
| Molar mass | 373.537 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
CCCCCC1=C(C(=C(C(=O)C1=O)C/C=C(\C)/CCC=C(C)C)O)NCC
|
InChI=1S/C23H35NO3/c1-6-8-9-13-18-20(24-7-2)21(25)19(23(27)22(18)26)15-14-17(5)12-10-11-16(3)4/h11,14,24-25H,6-10,12-13,15H2,1-5H3/b17-14+ Key:MRCQPMQBCKEOCU-SAPNQHFASA-N
|
EHP-102, also known as VCE-003.2, is a cannabinoid CB2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease.[1][2][3][4] It is taken orally.[1] The drug is a derivative of cannabigerol (CBG).[4] It is under development by Emerald Health Sciences.[1][2][3] As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.[1][2][3]
See also
References
- ^ a b c d e "EHP 102". AdisInsight. 28 February 2024. Retrieved 2 June 2026.
- ^ a b c "Delving into the Latest Updates on EHP-102 with Synapse". Synapse. 24 May 2025. Retrieved 2 June 2026.
- ^ a b c Shaffer C (1 March 2020). "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News. 40 (3): 52–55. doi:10.1089/gen.40.03.14. ISSN 1935-472X.
- ^ a b Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. (July 2016). "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports. 6 29789. doi:10.1038/srep29789. PMC 4949444. PMID 27430371.
|
|---|
Phytocannabinoids (comparison) | | Cannabibutols | |
|---|
| Cannabichromenes | |
|---|
| Cannabicyclols | |
|---|
| Cannabidiols | |
|---|
| Cannabielsoins | |
|---|
| Cannabigerols | |
|---|
| Cannabiphorols | |
|---|
| Cannabinols |
- CBN
- CBNA
- CBN-C1
- CBN-C2
- CBN-C4
- CBNM
- CBND
- CBNP
- CBVD
|
|---|
| Cannabitriols | |
|---|
| Cannabivarins | |
|---|
| Delta-3-tetrahydrocannabinols | |
|---|
| Delta-4-tetrahydrocannabinols | |
|---|
| Delta-7-tetrahydrocannabinols | |
|---|
| Delta-8-tetrahydrocannabinols | |
|---|
| Delta-9-tetrahydrocannabinols | |
|---|
| Delta-10-Tetrahydrocannabinols | |
|---|
| Delta-11-Tetrahydrocannabinols | |
|---|
| Miscellaneous cannabinoids | |
|---|
| Active metabolites | |
|---|
|
|---|
| Endocannabinoids | |
|---|
Synthetic cannabinoid receptor agonists / neocannabinoids | Classical cannabinoids (dibenzopyrans) | |
|---|
Non-classical cannabinoids | |
|---|
| Adamantoylindoles | |
|---|
| Benzimidazoles | |
|---|
| Benzoylindoles | |
|---|
| Cyclohexylphenols | |
|---|
| Eicosanoids | |
|---|
Indazole-3- carboxamides | |
|---|
| Indole-3-carboxamides | |
|---|
| Indole-3-carboxylates | |
|---|
| Naphthoylindazoles | |
|---|
| Naphthoylindoles | |
|---|
| Naphthoylpyrroles | |
|---|
| Naphthylmethylindenes | |
|---|
| Naphthylmethylindoles | |
|---|
| Phenylacetylindoles | |
|---|
| Pyrazolecarboxamides | |
|---|
Tetramethylcyclo- propanoylindazoles | |
|---|
Tetramethylcyclo- propanoylindoles | |
|---|
| Others | |
|---|
|
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands | |
|---|
Endocannabinoid enhancers (inactivation inhibitors) | |
|---|
Anticannabinoids (antagonists/inverse agonists/antibodies) | |
|---|
|
|
|---|
Receptor (ligands) | | CB1Tooltip Cannabinoid receptor 1 | Agonists (abridged, full list) | |
|---|
| Inverse agonists | |
|---|
| Antagonists | |
|---|
|
|---|
| CB2Tooltip Cannabinoid receptor 2 | | Agonists |
- 2-AG
- 2-AGE (noladin ether)
- 3,3'-Diindolylmethane
- 4-O-Methylhonokiol
- α-Amyrin · β-Amyrin
- A-796,260
- A-834,735
- A-836,339
- AM-1172
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CB-13
- CBS-0550
- CP 55,940
- EHP-102 (VCE-003.2)
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Lenabasum (anabasum)
- Magnolol
- MDA-19
- Nabitan
- NADA
- Olorinab (APD-371)
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
|---|
| Antagonists | |
|---|
|
|---|
NAGly (GPR18) | |
|---|
| GPR55 | |
|---|
| GPR119 | |
|---|
|
|---|
Transporter (modulators) | | eCBTsTooltip Endocannabinoid transporter | |
|---|
|
|---|
Enzyme (modulators) | | FAAHTooltip Fatty-acid amide hydrolase 1 | |
|---|
| MAGL | |
|---|
| ABHD6 |
- Inhibitors: JZP-169
- JZP-430
- KT182
- KT185
- KT195
- KT203
- LEI-106
- ML294
- ML295
- ML296
- UCM710
- WWL-70
|
|---|
| ABHD12 | |
|---|
|
|---|
| Others |
- Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
- ARN-272 (FAAH-like anandamide transporter inhibitor)
|
|---|
- See also
- Receptor/signaling modulators
- Cannabinoids (cannabinoids by structure)
|
|
|---|
| PPARαTooltip Peroxisome proliferator-activated receptor alpha | |
|---|
| PPARδTooltip Peroxisome proliferator-activated receptor delta |
- Antagonists: FH-535
- GSK-0660
- GSK-3787
|
|---|
| PPARγTooltip Peroxisome proliferator-activated receptor gamma |
- Antagonists: FH-535
- GW-9662
- SR-202
- T-0070907
|
|---|
| Non-selective | |
|---|
- See also
- Receptor/signaling modulators
|